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ABSTRACT

Disclosed herein are novel methods and compositions for
treating and/or preventing hair loss in patients. Specifically
exemplified herein are compositions containing a modified
pyrimidine that are topically applied to a scalp of an patient.
Typically, the patient has androgenic alopecia, alopecia
greata, postpartum alopecia or telogen effluvium.
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COMPOSITIONS FOR TREATING OR
DELAYING THE ONSET OF HAIR LOSS

FIG. 4: shows predominant hair re-growth (in white circle)
in mouse #2 (A) using a topical application of3.0 mg/ml. B)
mouse prior to experiment. C) shaved area (in white circle)
Below show immunohistochemistry of3.0 mg/ml (D) where
an overwhelming number ofBrdU positive (green) cells coincides with the area of hair re-growth and 1.5 mg/ml (E) where
proliferation is at an increase.

CROSS REFERENCE TO RELATED
APPLICATIONS
This application is related to U.S. Provisional patent application No. 61/097,443; filed Sep. 16, 2008 to which priority is
claimed under 35 USC 119. This provisional application is
incorporated herein in its entirety.
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DETAILED DESCRIPTION
10

BACKGROUND
Alopecia affects millions of men and women annually.
95% of all hair loss is caused by Androgenic Alopecia (a
genetically inherited hair loss condition, otherwise known as
pattern baldness). The remaining 5% of hair loss can be
associated with a variety of health conditions, stress and
trauma, diet and nutrition, environmental toxins, and medications. Currently, five out of 10 men and 21 million women
will experience hair loss and the psychological affects associated with this condition. In the case of Androgenic Alopecia, testosterone is converted in the body to DHT (Di-hydrotesterone) by the enzyme SAR (5 Alpha-deductase). DHT
binds to specific points in the hair follicle called Androgen
Receptor Sites (ARS) and this causes a mineralization which
shrinks the diameter of the hair and reduces the time spent in
the growth cycle, known as the anagen phase. Other known
types of hair loss can be diagnosed as Telogen Effluvium,
Traction or Traumatic Alopecia, Alopecia Areata, and Postpartum Alopecia. Telogen Effluvium produces a premature
shedding of hair that is in resting or telogen phase. Causes of
Telogen Effluvium can be contributed to illness, shock, and
medication and can usually be reversed upon the removal of
conditions. Traction or Traumatic Alopecia is demonstrated
by patchy, scattered hair loss and is induced by heating elements used to dress hairor binding hair with bands; this is also
reversible by removal of conditions. Alopecia Areata produces round irregular patchy spots of hair loss and the cause
is unknown. But the commonality of all types of hair loss is
the psychological effect it has on the men and women who
experience these conditions.
BRIEF DESCRIPTION OF DRAWINGS
The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
office upon request and payment of the necessary fee.
FIG. 1 The pictures A-Dare 20 uM sagittal sections of the
dermal layer of mouse #1 A)Control (50% ETOH) at !Ox B;
stained with anti-BrdU (green) 1.5 mg/ml NBI-18 at 5x magnification; stained with anti-BrdU (green) and dapi (blue) C)
3.0 mg/ml NBI-18 at !Ox magnification; stained with antiBrdU (green) D) 3.0 mg/ml NBI-18 at !Ox magnification;
stained with anti-BrdU (green).
FIG. 2 PicturesA-C are all of mouse #4. A) Prior to experiment (nothing has been done to the animal. B) The circled
area shows where the hair has been shaved and what appears
to look like a water drop is the application of solutions prior to
evaporation (this picture was taken on the first day of application). C) The circled area shows where there was a predominant re-growth of hair.
FIG. 3. Immunohistochemistry: below A) control B) 3.0
mg/ml (circled area above in C where there is demonstrative
hair re-growth.
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Recently, in the course of evaluating factors that influence
stem cell proliferation, we made a provocative discovery. A
heterocyclic pyrimidine molecule NBI-18 (2-piperadino-6methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d]pyrimidine
maleate; Mwt. 349.54), previously described as having possible neurotrophic activity, can stimulate the proliferation of
human NSCs in culture. The increase in proliferation was
dose dependent in animal studies. We found that daily injections ofNBI-18 for five days led to stable neurogenesis at four
weeks in young and aged rodents alike. There were no discernible pathological effects, and no symptoms of toxicity
due to the treatment with NBI-18 throughout the experiment.
Based on these preliminary findings, we moved towards
developing a topical application in an attempt to increase cell
proliferation in a similar manner in relation to hair regeneration. C57 BL/6 mice were used to apply different concentrations ofNBI-18 on shaved areas of skin with the incorporation of BrdU to detect cell proliferation, followed by
immunohistochemistry. We were able to see an abundant
increase in proliferating cells in all concentrations applied in
comparison to the control area. More importantly, was the
visibly complete hair growth that was in the treated areas
compared to the non-treated areas. NBI-18 promises to be a
novel compound leading to the development of regenerative
therapeutics that can accelerate hair growth.
Recently, the inventors became intrigued by several reports
suggesting that a family of heterocyclic pyrrolopyrimidine
(PyP) compounds have a variety of growth promoting biological activities including increasing neurite outgrowth and
repair ofinjured peripheral nerves and muscle. U.S. Pat. Nos.
4,959,368; 5,976,523. One derivative of interest is heterocyclic pyrimidine molecule referred to herein as 'NBI-18'
(2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,
4-d]pyrimidine maleate; Mwt. 349.54). In other cell culture
studies using neurons isolated from rodent cortex, NBI-18
was reported to be active primarily in the presence of various
growth factors, including bFGF, nerve growth factor, EGF,
and insulin-like growth factor. U.S. Patent Pub 20030139410.
The mechanism of action of NBI-18 is not known, although
some evidence implies the activation of the MAPK (mitogen
activated protein kinase) pathway, a cascade that is also activated by peptide growth factors. It has been suggested that
NBI-18 promoted the survival of rodent cortical neurons by
reducing the rate of apoptosis, as measured by TUNEL
assays. NBI-18 has been tested in isolated animal modelsaxon growth in mice and muscle regeneration in rats-with
no evidence of mechanistic details relating to function.
Mechanism of action studies to find the drug target, are
planned as part of our ongoing research. Upon learning about
the availability ofNBI-18 family of molecules, it was hypothesized that the compounds may be involved in the proliferation process of Stem Cells and the inventors decided to examine the possible implication for genesis ofKeratinocyte Stem
Cells (KSCs) or possibly the human bulge cells which provide the niche for KSCs, in animal models. Early evidence
from rodent studies, suggests that NBI-18 is absorbed well
after intraperitoneal as well as oral administration and it has a

US 8,791,128 B2
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4

tl/2>>4 h in rat circulation as shown by HPLC analysis.
NBI-18 can be extracted 24 hours-post-injection from the
epidermis of treated mice and the compound was not
mutagenic, as indicated by a third party Ames test.
Based on the inventors' realizations, the decision was made
to test NBI-18 in a topical application study to induce the
genesis or re-growth of hair. Varying doses ofNBI-18 [0.75
mg/ml, 1.5 mg/ml, 3.0 mg/ml, and control (50% ETOH)] was
delivered in 5 ul drops to shaved locations on the back of C57
BL/6 mice. The varying doses were given 5 consecutive days
and on day 4 and 5 BrdU (100 mg/kg, ip) was injected.
Immunohistochemistry suggest a vast increase in Brdu+cells
throughout the NBI-18 concentrations in comparison to the
control, which didn't receive NBI-18. However, the most
impressive data was the visible re-growth of hair in the treated
areas, near to its original length within 7 days. The control or
untreated areas showed no visible re-growth within the 7 day
time frame. NBI-18 has proven to produce a desired affect in
rodent models that show a predominant re-growth of hair
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--CH 2 0COC 2 H5 , and X represents
NH, =N--CH 3 ,
N-COCH 3 , =N--COOC 2 H5 ,
N-S0 2 CH 3 , =CH 2 ,
=CHCH 3 , =CHC 2 H5 , - 0 - or - S - in which ph stands
for a phenyl group.
Typical illustrative compounds of formula (1) include:
2-piperazino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]
pyrimidine,
2-( 4- Methylpiperazino-6-methy1-5-oxo-5 ,6-dihydro-(7H)
pyrro[3,4-d]pyrimidine,
2-( 4- Ethylpiperazino-6-methy1-5-oxo-5 ,6-dihydro-(7H)
pyrro[3,4-d]pyrimidine,
2-Piperidino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]
pyrimidine,
2-( 4-Methylpiperidino )-6-methyl-5-oxo-5,6-dihydro(7H)
pyrro[3,4-d]pyrimidine
2-( 4-Ethylpiperidino )-6-methyl-5-oxo-5,6-dihydro-(7H)
pyrro[3,4-d]pyrimidine
2-Morpholino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4d]pyrimidine,
2-Thiomorpholino-6-methyl-5-oxo-5 ,6-dihydro(7H)-pyrro
[3,4-d]pyrimidine,
2-piperazino-6-ethyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d]
pyrimidine,
2-piperazino-6-isopropyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4d]pyrimidine,
2-piperazino-6-n-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]
pyrimidine,
2-piperazino-6-sec.-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,
4-d]pyrimidine,
2-piperazino-6-t-butyl-5-oxo-5,6-dihydro(7H)-pyrro[3,4-d]
pyrimidine,
2-piperazino-4,6-dimethyl-5-oxo-5,6-dihydro(7H)-pyrro[3,
4-d]pyrimidine,
2-piperazino-6, 7-dimethyl-5-oxo-5 ,6-dihydro(7H)-pyrro [3,
4-d]pyrimidine,
2-piperazino-6, 7, 7-trimethyl-5-oxo-5,6-dihydro-(7H)pyrro
[3,4-d]pyrimidine,
2-Piperidino-4,6-dimethyl-5-oxo-5,6-dihydro(7H)-pyrro[3,
4-d]pyrimidine,
2-Piperidino-6, 7, 7-trimethyl-5-oxo-5,6-dihydro-(7H)pyrro
[3,4-d]pyrimidine,
2-piperazino-7-methy1-6-ethyl-5-oxo-5 ,6-dihydro-(7H)
pyrro[3,4-d]pyrimidine, and
2-piperazino-4-methyl-6-ethyl-5-oxo-5,6-dihydro-(7H)
pyrro[3,4-d]pyrimidine.
Typical illustrative compounds of formula (2) include:
2-piperazino-7-methy1-6-oxo-5, 6-dihydro(7H)pyrro-[2,3-d]
pyrimidine,
2-( 4-Methylpiperazino )-7-methyl-6-oxo-5,6-dihydro(7H)
pyrro[2,3-d]pyrimidine
2-( 4-Ethylpiperazino )-7-methyl-6-oxo-5,6-dihydro-(7H)
pyrro[2,3-d]pyrimidine
2-( 4-N-Acetylpiperazino )-7-methyl-6-oxo-5,6-dihydro(7H)
pyrro[2,3-d]pyrimidine,
2-Piperidino-7-methy1-6-oxo-5, 6-dihydro(7H)pyrro-[2,3-d]
pyrimidine,
2-( 4-Methylpiperidino )-7-methyl-6-oxo-5,6-dihydro(7H)
pyrro[2,3-d]pyrimidine
4-(Ethylpiperidino )-7-methyl-6-oxo-5,6-dihydro-(7H)pyrro
[2,3-d]pyrimidine,
2-Morpholino-7-methy1-6-oxo-5, 6-dihydro(7H)pyrro-[2,3d]pyrimidine,
2-Thiomorpholino-7-methyl-6-oxo-5,6-dihydro(7H)-pyrro
[2,3-d]pyrimidine,
2-Piperidino-7-ethy1-6-oxo-5, 6-dihydro(7H)pyrro-[2,3-d]
pyrimidine,

NBI-18 treatment will lead to greater cytogenesis and eventually lead to a commercial product that will eradicate hair
loss. These studies will be further described in the Examples
provided below.
Accordingly, in one embodiment, the subject invention
pertains to a method of increasing thickness of hair (i.e.
number of hair fibers per surface area) and/or number hair
follicles actively producing hair fibers in a human or nonhuman subject that comprises the administration of a hair-enhancing composition that contains a hair producing agent
(HPA). U.S. Pat. No. 5,976,523 (523 patent) and U.S. Pat. No.
4,959,368 ('368 patent) teach a number of compounds that
may be used as wound healing agents. The '523 patent
teaches that the wound healing agents described therein act by
potentiating growth factors and cytokines released in tissues
as a result of injury or wounding of tissues. Essentially, the
'523 patent teaches that the agents stimulate the migration of
cells toward the wound. The present inventors have discovered that the same agents actually stimulate the proliferation
of stem cells, which in tum, led to the discovery that the
agents may be used in circumstances where tissues have not
been wounded.
Accordingly, the agents presented in the '523 patent and
'368 patent are incorporated herein by reference for disclosure ofHPA agents. Also see U.S. Patent Pub 20080124306
Formulas 1 and 2 as set forth in the' 523 patent are provided:
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wherein R 1 to R 8 independently represent a hydrogen atom, a
lower
alkyl
(especially
C 1 -C 7
alkyl)
group,
CH 3 0CH 2 CH 2 - , -CH 2 CONH 2 , -COCH 3 , --COC 2 H5 or
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2-Piperidino-7-n-propy1-6-oxo-5, 6-dihydro(7H)-pyrro [2,3d]pyrimidine,
2-Piperidino-7-isopropyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2,3d]pyrimidine,
2-Piperidino-7-n-buty1-6-oxo-5 ,6-dihydro(7H)-pyrro [2,3-d]
pyrimidine,
2-Piperidino-7-t-butyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2,3-d]
pyrimidine,
2-Piperidino-5-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]
pyrimidine,
2-piperazino-5-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]
pyrimidine,
2-piperazino-4, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2,
3-d]pyrimidine,
2-Piperidino-5, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2,
3-d]pyrimidine,
2-Piperidino-5, 5, 7-trimethy1-6-oxo-5 ,6-dihydro-(7H)pyrro
[2,3-d]pyrimidine,
2-piperazino-5, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2,
3-d]pyrimidine,
2-piperazino-5, 5, 7-trimethy1-6-oxo-5 ,6-dihydro-(7H)pyrro
[2,3-d]pyrimidine,
2-Piperidino-4-methyl-7-ethyl-6-oxo-5,6-dihydro-(7H)
pyrro[2,3-d]pyrimidine, and
2-Piperidino-5-methyl-7-ethyl-6-oxo-5,6-dihydro-(7H)
pyrro[2,3-d]pyrimidine.
In certain embodiments the pyrimidine derivative of formula (1) is NBI-18, or 2-piperadino-6-methyl-5-oxo-5,6-dihydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4 H4 0 4
maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incorporated by reference herein. In certain in vivo embodiments,
the pyrimidine derivatives of formulae (I) and (II) is administered at a concentration of between about 0.01 mg/kg/day to
50 mg/kg/day, more preferably between about 0.1 mg/kg/day
to 10 mg/kg/day, even more preferably between about 1
mg/kg/day to 5 mg/kg/day, and even more preferably about 3
mg/kg/day. In these embodiments, the pyrimidine derivatives
of formulae (I) and (II) is administered for between about 1
and 60 days, or more preferably between about 1 and 30 days,
ormorepreferablybetweenabout 1and15 days, orevenmore
preferably between about 1 and 10 days, or more preferably
between about 2 and 7 days, or even more preferably about 5
days. In certain others of these embodiments, the methods
further comprise the step of administering a growth factor. In
certain embodiments, the growth factor comprises fibroblast
growth factor, epidermal growth factor or a combination
thereof.
Pharmaceutical compositions comprising the active compounds of the invention may be manufactured by means of
conventional mixing, dissolving, granulating, dragee-making
levigating, emulsifying, encapsulating, entrapping or lyophilization processes. The compositions may be formulated
in conventional manner using one or more physiologically
acceptable carriers, diluents, excipients or auxiliaries which
facilitate processing of the active compounds into preparations which can be used pharmaceutically. The actual pharmaceutical composition administered will depend upon the
mode of administration. Virtually any mode of administration
may be used, including, for example topical, oral, systemic,
inhalation, injection, transdermal, etc.
The active compound may be formulated in the pharmaceutical compositions per se, or in the form of a pharmaceutically acceptable salt. As used herein, the expression "pharmaceutically acceptable salt" means those salts which retain
substantially the biological effectiveness and properties of the
active compound and which is not biologically or otherwise
undesirable. Such salts may be prepared from inorganic and

organic acids and bases, as is well-known in the art. Typically,
such salts are more soluble in aqueous solutions than the
corresponding free acids and bases.
For topical administration, the active compound( s) may be
formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as
those designed for transdermal, transmucosal oral or pulmonary administration.
Useful injectable preparations include sterile suspensions,
solutions or emulsions of the active compound( s) in aqueous
or oily vehicles. The compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent. The formulations for injection may be presented in
unit dosage form, e.g., in ampules or in multidose containers,
and may contain added preservatives.
Alternatively, the injectable formulation may be provided
in powder form for reconstitution with a suitable vehicle,
including but not limited to sterile pyrogen free water, buffer,
dextrose solution, etc., before use. To this end, the active
compound(s) may dried by any art-known technique, such as
lyophilization, and reconstituted prior to use.
For transmucosal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are known in the art.
For oral administration, the pharmaceutical compositions
may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised
maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose ); fillers (e.g., lactose, microcrystalline cellulose
or calcium hydrogen phosphate); lubricants (e.g., magnesium
stearate, talc or silica); disintegrants (e.g., potato starch or
sodium starch glycolate); or wetting agents (e.g., sodium
lauryl sulfate). The tablets may be coated by methods well
known in the art with, for example, sugars or enteric coatings.
Liquid preparations for oral administration may take the
form of, for example, elixirs, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such
liquid preparations may be prepared by conventional means
with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl
alcohol or fractionated vegetable oils); and preservatives
(e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
The preparations may also contain buffer salts, flavoring,
coloring and sweetening agents as appropriate. Preparations
for oral administration may be suitably formulated to give
controlled release of the active compound.
For buccal administration, the compositions may take the
form of tablets, chewing gum or lozenges formulated in conventional manner.
For rectal and vaginal routes of administration, the active
compound(s) may be formulated as solutions (for retention
enemas) suppositories or ointments containing conventional
suppository bases such as cocoa butter or other glycerides.
For administration by inhalation, the active compound(s)
can be conveniently delivered in the form of an aerosol spray
from pressurized packs or a nebulizer, with the use of a
suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
other suitable gas. In the case of a pressurized aerosol the
dosage unit may be determined by providing a valve to deliver
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a metered amount. Capsules and cartridges of e.g. gelatin for
use in an inhaler or insuffiator may be formulated containing
a powder mix of the compound and a suitable powder base
such as lactose or starch.
For prolonged delivery, the active compound(s) can be
formulated as a depot preparation, for administration by
implantation; e.g., subcutaneous, intradermal, or intramuscular injection. Thus, for example, the active ingredient may be
formulated with suitable polymeric or hydrophobic materials
(e.g., as an emulsion in an acceptable oil) or ion exchange
resins, or as sparingly soluble derivatives; e.g., as a sparingly
soluble salt
Alternatively, transdermal delivery systems manufactured
as an adhesive disc or patch which slowly releases the active
compound(s) for percutaneous absorption may be used. To
this end, permeation enhancers may be used to facilitate
transdermal penetration of the active compound(s). Suitable
transdermal patches are described in for example, U.S. Pat.
Nos. 5,407,713; 5,352,456; 5,332,213; 5,336,168; 5,290,561;
5,254,346; 5,164,189; 5,163,899; 5,088,977; 5,087,240;
5,008,110; and 4,921,475.
Alternatively, other pharmaceutical delivery systems may
be employed. Liposomes and emulsions are well-known
examples of delivery vehicles that may be used to deliver
active compounds(s). Certain organic solvents such as dimethylsulfoxide (DMSO) may also be employed, although usually at the cost of greater toxicity.
The pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or
more unit dosage forms containing the active compound(s).
The pack may, for example, comprise metal or plastic foil,
such as a blister pack. The pack or dispenser device may be
accompanied by instructions for administration.

EXAMPLE2
Toxicity Study
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Preparation ofNBI-18 Composition
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In preliminary studies, the inventors found that NBI-18
injections (5 mg/kg) increased proliferation of cells in the
brain ofrodents. In this study, the inventors determined a dose
range where keratinogenesis occurs in healthy mice to help us
learn about the fate of newly formed cells within the epidermis. This data enables selection of a relevant dose range for
treating hair loss conditions such as Androgenic Alopecia,
Alopecia Areata, Postpartum Alopecia and Telogen Effluvium using a topical application. Normal healthy C57 BL/6
mice exhibiting natural active behavior were used to test the
topical application ofNBI-18. In order for us to eliminate
unnecessary anesthesia, our vehicle of delivery was 50%
Ethanol (ETOH). NBI-18 was suspended in 50% ETOH
using the concentrations of 0.75 mg/ml, 1.5 mg/ml, 3.0
mg/ml, and control (50% ETOH) respectively.
Results. In using 50% ETOH as our delivery vehicle we
were able to demonstrate through immunohistochemistry, an
increased population in BrdU positive stained cells. This visible increase was incurred in all concentrations ofNBI-18 and
showed a dramatic elevation in BrdU positive stained cells in
comparison to the control which received just 50% ETOH.
Although the elevations in BrdU positive stained cells did not
demonstrate a dose dependent increase as one would expect,
this could be due to the probability of that each recurring
application was not placed in exactly the same area on some
of the mice. A more applicable delivery system will be developed in future studies.

A total of 16 male C57 BL/6 mice (12 weeks old) weighing
25-30 g were used to investigate the toxicity ofNBI-18. The
mice were maintained on a 12-h light/dark cycle, and had free
access to food and water through the study period. These
animals were housed four per cage. In this study, animals
were divided into four groups (four/group). Acute toxicity has
been tested up to 1000 mg/kg. NBI-18 (0, 100, 300,1000
mg/kg/day, i.p.) was injected for 7 days and for the control
group, the same volume of vehicle saline was injected. Bromodeoxyuridine (BrdU)(Sigma Chemical Co., St Louis,
Mo.), was injected (lOOmg/kg/day, i.p.) for the last three days
(days 5-7). For behavioral testing, rotarod and open field tests
were used to examine balance and coordination of mice
before, during and after NBI-18 injection. Also, postural
reflex and forelimb placing tests were performed to evaluate
the neurological functions for the animals. All the animals
were anesthetized with pentobarbital (i.p.) 48 h after the last
BrdU injection and immediately per fused with 4% paraformaldehyde fixative. The brains were immediately dissected,
post fixed for 24 hand processed for immunohistochemistry.
Results. The animals demonstrated no immediate behavioral or neurological changes in the study. They showed no
symptoms of toxicity due to the treatment with NBI-18
throughout the experiment. An Ames was conducted by a
third party company and the results were consistent showing
no mutagenesis or toxicity, suggesting that NBI-18 is safe and
won't have any adverse effects on the mice.
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In Vivo Study
A. Two C57 BL/6 mice were selected for the topical application study ofNBI-18. The mice were prepped by shaving
four specific locations lateral/dorsal in a circular pattern.
NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 1.5 mg/ml, 3.0 mg/ml, 6.0 mg/ml and control
(50% ETOH) respectively. The solutions were applied to the
center of these locations in a 5 ul dose for 5 consecutive days
and on days 4 and 5 BrdU ( 100 mg/K, ip) was injected. On day
7 the mice were euthanized using a high dose pentobarbital
(70 mg/kg, ip) and the treated epidermis was dissected and
placed into 4% paraformaldehyde fixative for 48 hour
Immunohistochemistry of epidermis. Epidermal sections
were mounted into square embedding molds with freezing
medium (O.C.T. compound, Tissue Tek), sliced in 20 uM
sections then mounted onto adhesive coated slides (Instrumedics, Inc) via tape transfer method. Slides were washed
with PBS then placed in 2NHCL for 30 minutes to induce
histone release. Slides were then washed again with PBS,
then blocked using 3% Donkey serum in PBST for 1 hour.
Primary anti-body suspended in blocking solution used was
anti-BrdU (sigma) at 1: 1000 overnight in 4C. Slide were
washed 3x then placed in secondary anti-body suspended in
blocking solution, FITC (Jackson ImmunoResearch) at 1:500
for 2 hours at room temperature then washed with PBS. Slides
were mounted using Vectashield with Dapi. Photographs
were taken using an inverted fluorescent microscope (Leica,
DMI 6000 B with Q-imaging Retiga exi camera).
Results. The Control (A) show a much reduced level of
BrdU signaling along with a nonmigration pattern; the new
cells are sporadic throughout the tissue sample. All of the
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NBI-18 treated samples (B-D) showed mass increases of
newly developed cells but most importantly they demonstrated an alignment towards migration patterns. FIG. 1.
B. Four C57 BL/6 mice were selected for the topical application study ofNBI-18. The mice were prepped by shaving
four specific locations lateral/dorsal in a circular pattern.
NBI-18 was delivered to the specified areas (right, counterclockwise from lowest to highest dose, then control) in concentrations of 0.75 mg/ml, 1.5 mg/ml, and 3.0 mg/ml, and
control (50% ETOH) respectively. The solutions were
applied to the center of these locations in a 5 ul dose for 5
consecutive days and on days 4 and 5 BrdU (100 mg/K, ip)
was injected. On day 7 the mice were euthanized using a high
dose pentobarbital (70 mg/kg, ip) and the treated epidermis
was dissected and placed into 4% paraformaldehyde fixative
for 48 hour.
Immunohistochemistry of epidermis. Epidermal sections
wer~ mounted into square embedding molds with freezing
medmm (0.C.T. compound, Tissue Tek), sliced in 20 uM
sections then mounted onto adhesive coated slides (Instrumedics, Inc) via tape transfer method. Slides were washed
with PBS then placed in 2N HCL for 30 minutes to induce
histone release. Slides were then washed again with PBS,
then blocked using 3% Donkey serum in PBST for 1 hour.
Primary anti-body suspended in blocking solution used was
anti-BrdU (sigma) at 1:1000 overnight in 4C. Slide were
washed 3x then placed in secondary anti-body suspended in
blocking solution, FITC (JacksonimmunoResearch) at 1:500
for 2 hours at room temperature then washed with PBS. Slides
were mounted using Vectashield with Dapi. Photographs
were taken using an inverted fluorescent microscope (Leica,
DMI 6000 B with Q-imaging Retiga exi camera).
Results. In all of the mice there were some varying levels of
increase in BrdU positive cells in comparison with the controls as shown in the immunohistochemistry. FIG. 3. However the most visible effect is the actual hair re-growth demonstrated in the pictures of the mice. FIG. 2 (mouse 4) and
FIG. 4 (mouse 2). Even though the locations ofhair re-growth
occur sporadically throughout the three concentrations of
NBI-18 (0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml.), there is absolutely no visible hair regeneration in the controls within the
same time constraints. This can be explained by the probability of each recurring applications ability was placed in exactly
the same area. A 5 ul drop onto the back of a moving mouse
allows for a possible missed location involving topical applications. However, the data clearly demonstrates the differences between the control and compound. A next feasible step
will be to test this compounds efficacy against similar proven
compounds such as minoxidil (Rogaine).
Discussion related to Examples 1-3. Preliminary studies
have shown that NBI-18 increases the number of BrdU positive cells in mice that have received a 5 day consecutive
topical application of 5 ul doses of0.7 5 mg/ml, 1.5 mg/ml, 3 .0
mg/ml and 50% ETOH (control). There are three cycles of
hair growth; the anagen phase (the growing phase), the catagen phase (where hair stops growing) and the Telogen phase
(which is the resting phase). The anagen phase last for

appx.1000 days but can range from 2-6 years and it is considered the "on" phase or growing phase. The catagen phase
lasts for only 1-2 weeks and during this phase the hair follicle
shrinks and starts to die; this is known as the transitional
phase. Telogen is the final phase often referred to as the
"resting" or "off' phase and this is when the hair follicle
renews or activates itself and a new hair in the anagen phase
develops pushing the old hair out. The mechanistic effect of
NBI-18 has on the stem cell population and how it directly
effects the hair follicles is still in the process of being elucidated. However, another study using the monoxidil showed
that in animal studies, topical minoxidil shortens the telogen
phase, causing premature entry of new hair from resting hair
follicles into anagen phase, thus producing a mechanistic
blocking effect of the natural pathways. In order to preserve
this mechanistic effect, the delivery dosage must continually
be maintained. In comparison our compound works on the
physiological pathway of the stem cell environment by
increasing the proliferation of endogenous cells. Once this
increase is achieved, usually within a 3-5 day treatment
schedule there is no need to continue using the compound.
The small molecule NBI-18 bypasses the ethical and technical issues associated with stem cell transplantation by
directly coaxing the production of healthy new endogenous
cells. NBI-18 and its variants represent a unique class of
synthetic heterocyclic compounds that are stable, orally bioavailability, and easily manufactured. The inventors are able
to use a compound that works synergistically with natural
stem cell growth factors to speed up cell proliferation. Such
compounds are a rare and valuable therapeutic candidate.
This idea delivers an exciting time for everyone. It is a new
and innovative drug that could change the aesthetics of people
everywhere. The adverse psychological effects caused hair
loss will no longer be an in issue in both men and women.
The disclosures of all cited patent documents, publications
and references are incorporated herein in their entirety to the
extent not inconsistent with the teachings herein. It should be
understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to be included within the
spirit and purview of this application and the scope of the
appended claims.
The invention claimed is:
1. A method ofinducing hair growth in a patient having hair
follicles comprising administering a therapeutically effective
amount of an hair producing (HPA) to said patient, wherein
said HPA is 2-Piperazino-6-methyl-5-oxo-5,6-dihydro(7H)
pyrro-[3,4-d]pyrimidine, or a pharmaceutically acceptable
salt thereof, and wherein said administering is topical administration.
2. The method of claim 1, wherein said HPA is in a composition further comprising a pharmaceutically acceptable
carrier.
3. The method of claim 2, wherein said composition is a
solution, gel, ointment, cream or suspension.
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